Dialysis

Successful Exit for Ariel Savannah Angel Partners with Sale of InnAVasc Medical, Inc.

Retrieved on: 
Friday, August 19, 2022 - 2:09pm
Technology, Angel Capital Association, ASAP, Dialysis, Quality of life, Investment, AVG, GLOBE, W. L. Gore & Associates, Bleeding, Risk, Mentorship, Â, Patient, Life insurance

Savannah, GA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Ariel Savannah Angel Partners (ASAP) has made a successful exit from one of their most medically advanced investments.

Key Points: 
  • Savannah, GA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Ariel Savannah Angel Partners (ASAP) has made a successful exit from one of their most medically advanced investments.
  • InnAVasc Medical, Inc. is a medical device company focused on the design and development of products for vascular access for hemodialysis.
  • Ariel Savannah Angel Partners is a member-led business angel group that is committed to finding, funding, mentoring, and supporting great young companies from pitch through to development, scale-up, and successful exit.
  • ASAP is a proud member of the Angel Capital Association, the largest angel professional development organization in the world.

Biohazard Bags Market to Reach $679.10 Million, Globally, by 2030 at 6.38% CAGR: Allied Market Research

Retrieved on: 
Friday, August 19, 2022 - 12:30pm
Transfer, Collection, Product type, Hospital, Enteral administration, Industry, Bag, Growth, Blood, Research, Anesthesia, Climate Monitoring and Diagnostics Laboratory, Dialysis, Drainage, AMR, Freezing, COVID-19, Stoma (medicine), Latex, Baggage, Tissue paper, Medical device, Avenue, Geography

PORTLAND, Ore., Aug. 19, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Biohazard Bags Market By Capacity (Less than 15 gallons, 15-30 gallons, More than 30 gallons), By Material Type (Polypropylene, Polyethylene, Plastic, High-Density Polyethylene, Others), By End-use (Hospitals, Clinics, & Diagnostic Lab, Home & Ambulatory Care, Pharmaceutical & Biopharmaceutical Industries): Global Opportunity Analysis and Industry Forecast, 2022-2031." According to the report, the global biohazard bags industry generated $396.60 million in 2021, and is estimated to reach $679.10 million by 2030, witnessing a CAGR of 6.38% from 2022 to 2030. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario.

Key Points: 
  • The report analyzes these key players of the global biohazard bags market.
  • The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.
  • Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat.
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions."

Biohazard Bags Market to Reach $679.10 Million, Globally, by 2030 at 6.38% CAGR: Allied Market Research

Retrieved on: 
Friday, August 19, 2022 - 12:30pm
Transfer, Collection, Product type, Hospital, Enteral administration, Industry, Bag, Growth, Blood, Research, Anesthesia, Climate Monitoring and Diagnostics Laboratory, Dialysis, Drainage, AMR, Freezing, COVID-19, Stoma (medicine), Latex, Baggage, Tissue paper, Medical device, Avenue, Geography

PORTLAND, Ore., Aug. 19, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Biohazard Bags Market By Capacity (Less than 15 gallons, 15-30 gallons, More than 30 gallons), By Material Type (Polypropylene, Polyethylene, Plastic, High-Density Polyethylene, Others), By End-use (Hospitals, Clinics, & Diagnostic Lab, Home & Ambulatory Care, Pharmaceutical & Biopharmaceutical Industries): Global Opportunity Analysis and Industry Forecast, 2022-2031." According to the report, the global biohazard bags industry generated $396.60 million in 2021, and is estimated to reach $679.10 million by 2030, witnessing a CAGR of 6.38% from 2022 to 2030. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario.

Key Points: 
  • The report analyzes these key players of the global biohazard bags market.
  • The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.
  • Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat.
  • Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions."

OM INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Outset Medical (OM) Investors with Over $300,000 Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Pending

Retrieved on: 
Thursday, August 18, 2022 - 8:22pm
FDA, Medicine, Steve Berman (lawyer), Dialysis, SEC, Federal Food, Drug, and Cosmetic Act, Hospital, Marketing, Person, Program, Fraud, NASDAQ, OM, News, Cosmetics, Complaint, Tobacco, Medical device, Life insurance, Pharmaceutical industry, Outset Media

This news drove the price of Outset Medical shares sharply lower.

Key Points: 
  • This news drove the price of Outset Medical shares sharply lower.
  • If you invested in Outset and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Outset should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

eHealth Exchange and CRISP Shared Services Announce QHIN Intentions

Retrieved on: 
Thursday, August 18, 2022 - 2:00pm
FDA, Dialysis, Indian Health Service, Social, GLOBE, Common, EHealth Exchange, Technology, Social Security Administration, Hospital, EHR, Motivation, Department, HIE, United States Department of Veterans Affairs, Food and Drug Administration, Department of Defence, Patient, Serving His Children, EHealth, CSS, Private sector, IHS, Exchange, Federation, Health information exchange, Solution, API, National, Food, Organization, Health insurance

VIENNA, Va., Aug. 18, 2022 (GLOBE NEWSWIRE) -- eHealth Exchange today announced that CRISP Shared Services,which provides health information exchange (HIE) and health data utility infrastructure for five statewide non-profit HIE organizations, intends to be the first participant in eHealth Exchanges anticipated Qualified Health Information Network (QHIN).

Key Points: 
  • VIENNA, Va., Aug. 18, 2022 (GLOBE NEWSWIRE) -- eHealth Exchange today announced that CRISP Shared Services,which provides health information exchange (HIE) and health data utility infrastructure for five statewide non-profit HIE organizations, intends to be the first participant in eHealth Exchanges anticipated Qualified Health Information Network (QHIN).
  • eHealth Exchange has long been a cornerstone of CRISP Shared Services ability to share data with organizations across the region, state, and country, including with the federal government, said Brandon Neiswender, acting chief executive officer for CRISP Shared Services.
  • The eHealth Exchange is thrilled that CRISP Shared Services is moving forward with TEFCA participation through our to-be-designated QHIN, said Jay Nakashima, executive director of eHealth Exchange.
  • We are diligently preparing to be a QHIN on behalf of members such as CRISP Shared Services.

Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)

Retrieved on: 
Thursday, August 18, 2022 - 6:00am
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Vasculitis, Receptor (biochemistry), Multimedia, Dialysis, Risk, NICE, Inflammation, C5a, National Health Service, Population, Neutrophil, Failure, University of Cambridge, ANCA, Atypical hemolytic uremic syndrome, ASX, Rituximab, European Commission, Steroid, CSL, Patient, Quality of life, Marketing, Cell, Hidradenitis suppurativa, Granulomatosis with polyangiitis, Anti-neutrophil cytoplasmic antibody, HS, Nephrology, MHRA, Prednisolone, Kidney, MPA, Fresenius Medical Care, GPA, Glucocorticoid, Lung, Microscopic polyangiitis, University, Cyclophosphamide, Time, Regulation of tobacco by the U.S. Food and Drug Administration, Medicine, Food, Adult, AAV, Disease, Health care, Pharmaceutical industry

We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.

Key Points: 
  • We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.
  • NICEs decision represents a major advancement for the treatment of GPA/MPA in the UK, said Prof. David Jayne, Professor of Clinical Autoimmunity, University of Cambridge.
  • Patients will now have access to a new therapy option that could help them optimize their treatment outcomes.
  • Tavneos was developed by ChemoCentryx, Inc., who is also developing Tavneos for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS).

OUTSET MEDICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Outset Medical, Inc. - OM

Retrieved on: 
Wednesday, August 17, 2022 - 3:54am
FDA, FREE, Dialysis, GLOBE, LLC, Blood, Patient, Lists of schools in England, Company, Lawyer, Water, District court, Nasdaq, Kidney failure, News, Outset Media, Medical device, Private investigator, Security (finance)

This action is pending in the United States District Court for the Northern District of California.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of California.
  • Outset investors should visit us at https://claimsfiler.com/cases/nasdaq-om/ or call toll-free (844) 367-9658.
  • CareDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • Outset and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

OUTSET MEDICAL LAWSUIT ALERT: Kaplan Fox & Kilshiemer LLP Notifies Outset Medical Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Tuesday, August 16, 2022 - 10:24pm
FDA, Dialysis, GLOBE, Securities Exchange Act of 1934, Notice, Class, Regulation of tobacco by the U.S. Food and Drug Administration, Company, WHY, NASDAQ, News, Food, FOX, Medical device

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical or the "Company) (NASDAQ: OM).

Key Points: 
  • NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical or the "Company) (NASDAQ: OM).
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey.
  • With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

OUTSET MEDICAL, INC. (NASDAQ: OM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Outset Medical, Inc. (NASDAQ: OM)

Retrieved on: 
Monday, August 15, 2022 - 9:00pm
FDA, Disclosure, Dialysis, Advertising, GLOBE, NEW, Securities Exchange Act of 1934, Investment, Sale, The Legal 500, Environment, Company, Lists of action films, Blood, Labour government, Marketing, Court, Patient, COVID-19, Lists of schools in England, Water, District court, NASDAQ, Kidney failure, News, Regulation of tobacco by the U.S. Food and Drug Administration, Chronic kidney disease, Food, Tobacco, Medical device, Pharmaceutical industry, Life insurance, Online gambling

NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) between September 15, 2020, and June 13, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.
  • Outset Medical is a medical technology company focused on kidney dialysis, the primary treatment for acute and chronic kidney failure.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Melissa D. Shah, MD is recognized by Continental Who's Who

Retrieved on: 
Monday, August 15, 2022 - 7:45pm
Brown University, Multimedia, Dialysis, Elective surgery, American Board of Commissioners for Foreign Missions, Johannes Hoffmann (vascular surgeon), Continental, Patient, Albany Medical College, Education, American Board of Surgery, Moyamoya disease, General surgery, Albany Medical Center, Vascular surgery, Physician, MD, Boston Medical Center, Varicose veins, Health, Dentistry, Biology

ALBANY, N.Y., Aug. 15, 2022 /PRNewswire/ -- Melissa D. Shah, MD, is being recognized by Continental Who's Who as a Trusted Healthcare Professional for her outstanding work as a Vascular Surgeon and in acknowledgment of her excellence at Albany Med Vascular Group.

Key Points: 
  • ALBANY, N.Y., Aug. 15, 2022 /PRNewswire/ -- Melissa D. Shah, MD, is being recognized by Continental Who's Who as a Trusted Healthcare Professional for her outstanding work as a Vascular Surgeon and in acknowledgment of her excellence at Albany Med Vascular Group.
  • A highly trained expert in her field, Dr. Shah has practiced at Albany Med Vascular Group for over 20 years.
  • Co-founded by Dr. Shah's father, the medical clinic is the largest provider of vascular surgery in the northeastern United States.
  • Today, many procedures pioneered by the Albany Med Vascular Group team are considered standard of care.